AngioDynamics Enrolls First Patient in Clinical Research Office of Endourological Society NanoKnife Safety and Efficacy Study

AngioDynamics

announced the enrollment of the first patient at Academic Medical Center, Amsterdam, The Netherlands, by the Clinical Research Office of the Endourological Society (CROES) in an investigator-led, multi-center study assessing the safety, efficacy and patient satisfaction of the NanoKnife System for the ablation of prostate cancer. This study is the first of two studies that will comprise the CROES project. A second, randomized study among 200 patients will begin after the conclusion of the safety study. The study titled, "The Safety and Efficacy of Irreversible Electroporation (IRE) for the Ablation of Prostate Cancer Assessed by Procedural Related Side Effects and Post Prostatectomy Histology: A Prospective Human In-Vivo Study," will enroll 16 patients who have been diagnosed with histopathologically confirmed, organ confined prostate cancer and are scheduled for a prostatectomy. Eligible patients will be asked to undergo treatment with NanoKnife System approximately 30 days prior to the prostatectomy.